The ATM program is effectively shut down for now, removing a near-term overhang. Monitor the company's cash runway and any new capital raise announcements (e.g., another S-3 takedown or registered direct offering) as the going-concern status suggests additional funding will eventually be needed. The stock may see a modest relief rally on reduced dilution fears.
Price Chart
Executive Summary
NanoViricides filed an amendment to its prospectus supplement that effectively pauses its at-the-market (ATM) offering program. The company has reached the one-third-of-public-float limit under General Instruction I.B.6 of Form S-3, having sold approximately $9.84 million in stock over the prior 12 months against a public float of $41.58 million. The ATM program is now inactive until the public float changes or exceeds $75 million, removing near-term dilution risk from this specific facility.
Key Facts
- Amendment No. 1 to Prospectus Supplement dated July 27, 2026 decreases the maximum amount eligible for sale under the ATM program to $0.
- The company has sold approximately $9,843,165 of common stock under General Instruction I.B.6 in the prior 12 months.
- Public float as of July 23, 2026 was $41,583,701, based on 22,356,829 non-affiliate shares at $1.86 per share.
- The ATM program is paused; no shares may currently be offered or sold through D. Boral Capital LLC under this prospectus supplement.
- Future sales could resume if public float changes, subject to the one-third-of-float limit, or if float exceeds $75 million.
Financial Impact
Removes up to ~$13.9M of potential future dilution (one-third of $41.6M public float minus $9.8M already sold). Near-term dilution risk from this ATM facility is eliminated.
Risk Factors
- Company remains a clinical-stage biotech with no revenue and a going-concern qualification; alternative financing (dilutive or otherwise) will likely be required.
- If public float increases significantly, the ATM program could reactivate, reintroducing dilution risk.
- The company has filed multiple S-3s and 424B5s in the past 24 months, indicating persistent capital needs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-086767 |
| Document: 0001104659-26-086767-index-headers.html | 0001104659-26-086767 |
| Document: 0001104659-26-086767-index.html | 0001104659-26-086767 |
| Document: 0001104659-26-086767.txt | 0001104659-26-086767 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 424B5 | $1.51 | awaiting T+60 | — | $1.36 (−9.89%) |
Oct 8, 2026 17d ago | DEF 14A | $1.31 | awaiting T+60 | — | $1.36 (+3.87%) |
Jul 27, 2026 13w ago | 424B5 | $1.54 $1.48 | ▲ +3.90% | ▲ +7.95% | $1.36 (+11.64%) |
Jul 27, 2026 13w ago | 424B5 | $1.54 $1.48 | ▼ −3.90% | ▼ −7.95% | $1.36 (−11.64%) |
Jun 29, 2026 17w ago | EFFECT | $1.37 $1.51 | ▼ −10.22% | ▼ −6.60% | $1.36 (+0.68%) |
Jun 16, 2026 18w ago | EFFECT | $1.36 $1.02 | ▼ −25.00% | ▼ −26.86% | $1.36 (+0.05%) |
Jun 15, 2026 18w ago | S-3 | $1.36 $1.02 | ▼ −25.00% | ▼ −26.86% | $1.36 (+0.05%) |
Jun 5, 2026 20w ago | S-3 | $1.43 $1.17 | ▲ +18.18% | ▲ +21.69% | $1.36 (+4.85%) |
May 18, 2026 23w ago | 424B5 | $1.51 $1.37 | ▲ +9.27% | ▲ +14.12% | $1.36 (+9.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers